ETFs Kamada Ltd.

KMDA

IL0010941198

Pharmaceuticals

Market Closed - TEL AVIV STOCK EXCHANGE 06:47:02 2026-10-16 EDT			5-day change	1st Jan Change
2,443.00 ^ILa	+0.33%		-1.01%	+8.10%

10-06	Kamada Launches Ustekinumab, Enoxaparin Biosimilars in Israel	MT
10-06	Kamada Ltd. Announces Expansion of Biosimilars Portfolio with Launch of Two Additional Products in Israel	CI

ETFs positioned on Kamada Ltd.

Name	YTD change	Weight	AuM
DIMENSIONAL INTERNATIONAL SMALL CAP ETF - USD	+9.22%	-	5,871 M€
ISHARES NASDAQ US BIOTECHNOLOGY UCITS ETF - USD	+20.43%	0.04%	1,079 M€
ISHARES NASDAQ US BIOTECHNOLOGY UCITS ETF (D) - USD	+19.96%	0.04%	78 M€
INVESCO NASDAQ BIOTECHNOLOGY ETF - USD	+18.61%	0.03%	81 M€
VANGUARD FTSE ALL-WORLD EX-US SMALL-CAP ETF - USD	+6.12%	0.01%	12,001 M€
DIMENSIONAL WORLD EQUITY ETF - USD	+12.50%	0%	1,674 M€
VANGUARD ALL-EQUITY ETF PORTFOLIO - CAD	+15.29%	0%	12,086 M€
CCM GLOBAL EQUITY ETF - USD	+13.63%	0%	1,199 M€
VANGUARD BALANCED ETF PORTFOLIO - CAD	+7.09%	0%	4,204 M€
AVANTIS INTERNATIONAL EQUITY ETF - USD	+9.31%	0%	18,816 M€

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

Employees

462

Sector

Pharmaceuticals

More about the company